Accelerating Gene Therapy Development With Media And Feed Panels

Effective therapies for genetic disorders are currently very limited due to the disorders' rarity and complexity. Despite the challenge, progress has made a significant leap in the last decade in the form of gene therapies. By targeting defective genes to restore cell or protein function, gene therapies aim to resolve the underlying causes of genetic disorders and provide one-time, curative treatments.

Adeno-associated virus (AAV) vectors have risen to be the leading gene therapy delivery platform, helping these therapies to reach their full potential when treating genetic disorders. As a result, gene therapy manufacturers are seeking ways to improve AAV production with a panel based approach to media and feed development.